Patents by Inventor Gregory D. Sempowski

Gregory D. Sempowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
    Patent number: 7041294
    Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1?(IL-1?) and interleukin-1? (IL-1?).
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: May 9, 2006
    Assignee: Duke University
    Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
  • Thymic atrophy
    Publication number: 20040131619
    Abstract: The present invention relates, in general, to thymic atrophy and, in particular, to a method of treating or preventing thymic atrophy in septic shock.
    Type: Application
    Filed: September 30, 2003
    Publication date: July 8, 2004
    Applicant: DUKE UNIVERSITY
    Inventors: Gregory D. Sempowski, Barton F. Haynes
  • Assay system
    Patent number: 6544747
    Abstract: The present invention relates, in general, to an assay system and, in particular, to a molecular assay system for the detection and/or quantification of mouse T cell receptor excision circles. The present system can be used to detect newly produced naïve T lymphocytes and to monitor thymic output and T lymphocyte immune reconstitution in mice.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: April 8, 2003
    Assignee: Duke University
    Inventors: Barton F. Haynes, Gregory D. Sempowski, Hua-Xin Liao
  • Assay system
    Publication number: 20020068297
    Abstract: The present invention relates, in general, to an assay system and, in particular, to a molecular assay system for the detection and/or quantification of mouse T cell receptor excision circles. The present system can be used to detect newly produced naïve T lymphocytes and to monitor thymic output and T lymphocyte immune reconstitution in mice.
    Type: Application
    Filed: October 11, 2001
    Publication date: June 6, 2002
    Inventors: Barton F. Haynes, Gregory D. Sempowski, Hua-Xin Liao
  • Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
    Publication number: 20010041180
    Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).
    Type: Application
    Filed: June 5, 2001
    Publication date: November 15, 2001
    Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
  • Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
    Patent number: 6270758
    Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: August 7, 2001
    Assignee: Duke University
    Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski